GFAP and neoplasm: LCL161 treatment significantly increased the expression of glial fibrillary acidic protein (GFAP), a major marker of reactive astrocytes [61], within the tumor border with no significant impact on expression distally (Fig. 5A–C), illustrating a greater tumor-local astrocyte involvement following SMC treatment.